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ABSTRACT 
Background: Both B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are 
widely used to aid diagnosis, assess the effect of therapy and predict outcomes in HFrEF. However, 
little is known about how these two peptides compare in HFrEF, especially with contemporary 
assays. Both peptides were measured at screening in the Prospective Comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-
HF). 
Methods: Eligibility criteria in PARADIGM-HF included New York Heart Association (NYHA) 
functional class II-IV, left ventricular ejection fraction (LVEF) ≤40% and elevated natriuretic 
peptides: BNP ≥150 pg/ml or NT-proBNP ≥600 pg/ml (for patients with HF hospitalization within 
12 months, BNP ≥100 pg/ml or NT-proBNP ≥400 pg/ml). BNP and NT-proBNP were measured 
simultaneously at screening and only patients who fulfilled entry criteria for both natriuretic 
peptides were included in the present analysis. The BNP/NT-proBNP criteria were not different for 
patients in atrial fibrillation (AF). Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m
2
 
was a key exclusion criterion.  
Results: The median baseline concentration of NT-proBNP was 2067 (Q1, Q3: 1217-4003 and 
BNP 318 (Q1, Q3: 207-559), and the ratio, calculated from the raw data, was approximately 6.25:1. 
This ratio varied considerably according to rhythm (AF 8.03:1; no AF 5.75:1) and with age, renal 
function and body mass index but not with LVEF. Each peptide was similarly predictive of death 
(all-cause, cardiovascular, sudden and pump failure) and heart failure hospitalization e.g. 
cardiovascular death: BNP HR 1.41 (95%CI 1.33-1.49) per 1 SD Increase, p<0.0001; NT-proBNP 
1.45 (1.36-1.54), p<0.0001. 
Conclusions: The ratio of NT-proBNP to BNP in HFrEF appears to be greater than generally 
appreciated, differs between patients with and without AF and increases substantially with 
  
increasing age and decreasing renal function. These findings are important for comparison of 
natriuretic peptide concentrations in HFrEF. 
 
Abbrevations 
proBNP = Pro B-type natriuretic peptide  
BNP = B-type natriuretic peptide  
NT-proBNP = N-terminal proBNP  
HFrEF = Heart failure and reduced ejection fraction  
NYHA = New York Heart Association  
LVEF = left ventricular ejection fraction  
AF = Atrial fibrillation  
MI = Myocardial infarction 
BMI = Body mass index 
ACE = Angiotensin converter enzyme 
ARB = Angiotensin receptor blocker  
MRA = Mineralocorticoid receptor antagonist 
SBP = Systolic blood pressure 
eGFR = estimated glomerular filtration rate 
CV = cardiovascular  
SD= standard deviation 
 
PARADIGM-HF = Prospective Comparison of ARNI with ACEI to Determine Impact on Global 
Mortality and Morbidity in Heart Failure trial  
Val-HeFT = Valsartan Heart Failure Trial  
 
 
 
 
  
What is new? 
 Although measurements of BNP and NT-proBNP are now routinely made in clinical 
practice, very little is known about how the values of each should be compared.  
 Overall, the ratio of NT-proBNP to BNP in PARADIGM-HF was approximately 6.25:1, 
substantially higher than the ratio commonly used in current guidelines and clinical trials.  
 Furthermore, this ratio varied considerably with age, renal function and body mass index, 
although not with LVEF. We also found that the NT-proBNP to BNP varied according to 
heart rhythm (AF 8.03:1; no AF 5.75:1), a finding not previously reported and not 
considered in current guidelines. 
What are the clinical implications? 
 There is no single, simple, conversion ratio of NT-proBNP to BNP and factors such as atrial 
fibrillation, age and renal function need to be taken into account. 
      
 
INTRODUCTION 
Pro B-type natriuretic peptide (proBNP) is secreted by cardiomyocytes in response to stretch and is 
quickly cleaved into two circulating fragments - the biologically active 32-amino acid C-terminal 
B-type natriuretic peptide (BNP) and the inert 76-amino acid N-terminal (amino-terminal) pro-B-
type natriuretic peptide (NT-proBNP).
1, 2
 Both fragments are routinely used to aid diagnosis of heart 
failure, predict outcomes and to monitor the effects of therapy.
3-6
 Despite their wide use, few studies 
have compared these two peptides in patients with chronic heart failure and although considered 
interchangeable, even things as fundamental as how their concentrations relate to each other in 
patients with heart failure are essentially unknown.
7, 8
 We have analyzed how the concentrations of 
  
BNP and NT-proBNP compare in patients with heart failure and reduced ejection fraction (HFrEF), 
and whether certain patient characteristics and comorbidities influence the circulating levels of 
these peptides differently. In particular, we focused on heart rhythm (atrial fibrillation or not). 
Although clinical trials apply different threshold values for inclusion of patients with and without 
atrial fibrillation, the ratio for patients with different rhythms varies greatly between studies. We 
have also examined whether age, renal function and body mass index as factors affect the 
concentration of each natriuretic peptide differently. In addition, we compared the predictive value 
of each peptide for non-fatal and a variety of fatal outcomes in HFrEF. We performed these 
analyses using data from the Prospective Comparison of ARNI with ACEI to Determine Impact on 
Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF) in which patients with 
HFrEF were randomized to treatment with either enalapril or sacubitril/valsartan. Both BNP and 
NT-proBNP were measured in most patients at screening in PARADIGM-HF.
9
 
METHODS 
Data, materials and statistical analyses are available upon request from a third party. 
Study design and patients 
The background, design and results of PARADIGM-HF are published previously.
9-11
 In brief, 8399 
patients in New York Heart Association (NYHA) functional class II-IV with a left ventricular 
ejection fraction (LVEF) ≤40% receiving recommended treatment for HFrEF including an 
angiotensin converter enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a beta-
blocker (unless contraindicated) and a mineralocorticoid receptor antagonist (MRA), if indicated, 
were enrolled. Patients were required to have a plasma BNP ≥150 pg/ml (or NT-proBNP ≥600 
pg/ml), or a BNP ≥100 pg/ml (or NT-proBNP ≥400 pg/ml) if there had been a hospitalization for 
heart failure within the past 12 months. There was no difference in entry BNP or NT-proBNP 
requirement for patients with or without atrial fibrillation. The key exclusion criteria included 
  
intolerance of an ACE inhibitor or ARB, a history of angioedema, symptomatic hypotension, a 
systolic blood pressure (SBP) <100 mmHg at screening (<95 mmHg at randomization), an 
estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m
2
, and a serum potassium level >5.2 
mmol/l at screening (>5.4 mmol/l at randomization). Patients were randomized to 
sacubitril/valsartan (formerly known as LCZ696) or enalapril. Presence of atrial flutter or 
fibrillation was based on the rhythm present on the screening ECG. History of diabetes was based 
on investigator reported diagnosis of diabetes, irrespective of HbA1c level at screening. The trial 
was approved by the ethics committee at each study center. All the patients provided written 
informed consent. 
 
Natriuretic peptide measurements 
Blood was collected at the screening visit. Plasma was isolated and immediately frozen at -20 
degrees Celsius. On the same day, samples were shipped on dry ice to the closest of six designated 
regional laboratories affiliated with the central laboratory run by Quintiles Durham, NC (now 
IQVIA). The same assay kits were used to measure each peptide at each site. Specifically, 
NTproBNP was measured using the Roche Elecys proBNP assay (Roche Diagnostics, Indianapolis, 
IN) and BNP using the Advia Centaur assay (Siemens Healthcare Diagnostics, Tarrytown, NY) as 
described previously.
10,11
  
 
Outcomes 
The median follow-up time in PARADIGM-HF was 27 months. The primary endpoint was a 
composite of cardiovascular death or heart failure hospitalization; we analyzed this, its components 
(cardiovascular death and heart failure hospitalization), the two major modes of cardiovascular 
death (sudden death and death due to worsening heart failure/pump failure) and all-cause mortality. 
  
We investigated the relationship between BNP and NT-proBNP and compared their predictive 
value for the outcomes described above. We also looked at the ratio of NT-proBNP to BNP and 
how different clinical characteristics affected this ratio.    
 
Statistical analyses 
Baseline characteristics are described by use of proportions for categorical variables and means with 
standard deviations or medians with quartiles for continuous variables. Differences in baseline 
characteristics between patients with a NT-proBNP/BNP ratio above or below the median were tested 
by use of a χ2-test for categorical variables and ANOVA or Kruskal Wallis test for continuous 
variables. The relationship between BNP and NT-proBNP was assessed using the Pearson correlation 
coefficient. Multivariable linear regression models were used to explore the association between age, 
sex, NYHA class, heart failure duration, prior heart failure hospitalization, body mass index (BMI), 
creatinine, LVEF, heart rate, atrial fibrillation (AF), myocardial infarction (MI), stroke and diabetes and 
NT-proBNP/BNP ratio.  Cox proportional hazard models were used to compare the risk of all-cause 
mortality, modes of death (cardiovascular, sudden and pump failure) and heart failure hospitalization 
according to level of BNP and NT-proBNP at baseline. The Cox regression models were adjusted for 
age, sex, treatment effect, race, region, LVEF, NYHA class, BMI, heart rate, systolic blood pressure, 
creatinine, prior heart failure hospitalization, heart failure duration, AF, MI, stroke and diabetes. The 
assumption of linearity in relation to outcomes in multivariable linear regression and Cox proportional 
hazard models was tested for age, LVEF, BNP and NT-proBNP. Log (-log(survival)) curves were used 
to evaluate the proportional hazard assumption.  Model discrimination was tested by use of Harrell’s C-
statistic.
12
 P-values < 0.05 were considered significant. Analyses were performed by use of Stata 
version 15 and R version 3.5.1.  
 
  
  
  
RESULTS 
Baseline characteristics 
Of all patients enrolled, 6438 (77%) fulfilled both the BNP and NT-proBNP requirements at 
screening and they were included in this substudy. The baseline characteristics of patients in 
PARADIGM-HF have been described in detail.
9, 11
 
 
Association between BNP and NT-proBNP and influence of baseline characteristics  
In the overall cohort, the median BNP was 318 (IQR 207-559) pg/ml and the median NT-proBNP 
was 2067 (IQR 1217-4003) pg/ml. There was a linear correlation between log BNP and log NT-
proBNP with a correlation coefficient of 0.81 (Figure 1a). The median NT-proBNP/BNP ratio in the 
overall study population was 6.25 (IQR 4.52-8.81):1. The NT-proBNP/BNP ratio was consistent 
across deciles of BNP (Figure 2a). Patients with a median NT-proBNP/BNP ratio >6.25 were older 
(mean age 66 years compared with 61 years in patients with NT-proBNP/BNP ratio ≤6.25), more 
were women (23% vs 19%) and Caucasian (69% vs 62%) and fewer had an ischemic etiology (57% 
vs 64%) or history of myocardial infarction (38% vs 49%) [Table 1]. Patients with a median NT-
proBNP/BNP ratio >6.25 also had worse kidney function (eGFR: 62 mL/min per 1.73 m
2
 vs 70 
mL/min per 1.73 m
2 
in patients with NT-proBNP/BNP ratio ≤6.25) and more had a history of AF 
(40% vs 28%) as well as AF on their screening ECG (36% vs 15%) [Table 1]. The NT-
proBNP/BNP ratio decreased in patients treated with sacubitril/valsartan (Supplementary figure 1).  
 
NT pro BNP/BNP ratio according to baseline rhythm and interaction with other characteristics 
In patients without atrial fibrillation, the median BNP was 329 (IQR 210-574) pg/ml and the 
median NT-proBNP was 1938 (1127-3750) pg/ml; in patients with atrial fibrillation the median 
BNP was 295 (IQR 203-520) pg/ml and the median NT-proBNP was 2480 (1517-4519) pg/ml. 
  
Among patients not in atrial fibrillation, the linear correlation between log BNP and log NT-
proBNP was 0.83; in patients in atrial fibrillation it was 0.79 (Figure 1b and 1c). The NT-
proBNP/BNP ratio varied considerably according to AF status: 5.75 (IQR 4.23-7.95):1 in patients 
without atrial fibrillation, compared to 8.03 (IQR 5.88-10.80):1 in patients with atrial fibrillation; 
this difference was consistent across all BNP deciles (Figure 2b and Figure 2c). In both rhythm 
groups, the ratio increased with increasing age and decreasing kidney function, was lower among 
obese patients, but was constant across the range of LVEF included in the trial (Figure 3).  
 
Independent predictors of the NT-proBNP/BNP ratio 
In multivariable linear regression analyses, older age, male sex, higher creatinine and atrial 
fibrillation were significantly associated with a higher NT-proBNP /BNP ratio (there was also a 
weak association with stroke). Conversely, obesity and history of myocardial infarction were 
associated with a lower NT-proBNP/BNP ratio (Table 2).  
 
Prognostic value of NT-proBNP and BNP 
Higher concentrations of each of NT-proBNP and BNP were associated with a higher risk of death 
from any cause, cardiovascular death, sudden death and pump failure death, as well as heart failure 
hospitalization (Table 3). The ratio of NT-proBNP /BNP was not associated with risk of any of 
these outcomes. The added discriminatory power, i.e. the ability to better separate patients at higher 
risk from those at lower risk, of NT-proBNP and BNP is outlined in Table 4. Each peptide provided 
incremental prognostic information when added to multivariable models including other recognized 
prognostic factors. The performance of NT-proBNP and BNP in each of these multivariable 
predictive models was similar. The ratio of NT-proBNP/BNP did not add prognostic information to 
the multivariable model for any outcome.  
  
DISCUSSION 
In patients with HFrEF, predominantly in NYHA class II and III, the NT-proBNP to BNP ratio was 
6.25:1, substantially higher than the ratio commonly applied in guidelines and clinical trials. For 
example, in the European Society of Cardiology guidelines, the “rule-out” threshold recommended 
is 35 pg/ml for BNP and for NT-proBNP is 125 pg/ml (ratio 3.6).
13
 In the Canadian Cardiovascular 
Society guidelines these thresholds are 50 pg/ml and 125 pg/ml, respectively (ratio 2.5) and in the 
National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand the 
corresponding values are 100 pg/ml and 300 pg/ml (ratio 3.0).
14, 15
 No specific thresholds are 
recommended in US guidelines.
16
 While it is possible that the relationship between NT-proBNP and 
BNP concentration is different than in patients with suspected heart failure compared to those with 
established HFrEF, one other sizeable study of patients in an emergency department reported a NT-
proBNP to BNP ratio of 5.7, similar to what we calculated.
17
 The NT-proBNP to BNP “conversion” 
ratio of between 3 and 4 to 1, used in recently completed and ongoing clinical trials in heart failure, 
is also substantially lower than the ratio we found in our study of HFrEF patients in which both 
peptides were measured in the same blood sample.  
As reported previously, many of the clinical variables that influence the circulating concentration of 
each natriuretic peptide, particularly age and eGFR (which are clearly related), also influenced the 
ratio of the two peptides in the present study. The increase in ratio with declining renal function 
was particularly notable, in keeping the closer association between NT-proBNP and eGFR, 
compared with BNP and eGFR (probably because, unlike BNP, NT-proBNP is believed to be 
removed mainly or exclusively from the circulation by renal excretion). The variation in plasma 
concentrations in relation to other patient factors has been used as an argument for thresholds 
tailored to patient characteristics and the recent National Heart Foundation of Australia/Cardiac 
Society of Australia and New Zealand guidelines recommend “rule-in” NT-proBNP thresholds 
  
stratified by age.
15
 Specifically, for age <50 years, 50-75 years and >75 years, the thresholds 
recommended are 450, 900 and 1800 pg/ml, respectively. Similar stratification is not provided for 
BNP, with a single “rule-in” threshold of 400 pg/ml recommended. 
Surprisingly, no major guideline differentiates between patients with and without atrial fibrillation, 
despite this arrhythmia clearly increasing natriuretic peptide levels.
18, 19
 We found that the NT-
proBNP to BNP ratio was 8.03:1 in patients with atrial fibrillation, compared to 5.75:1 in those not 
in atrial fibrillation. It is unclear why the ratio should vary according to rhythm and the influence of 
the other clinical characteristics modifying natriuretic peptide concentrations was as powerful in 
patients with atrial fibrillation as in those without. Consequently, for example, the NT-
proBNP/BNP ratio in the oldest patients was approximately 10:1 for those in atrial fibrillation 
compared with around 6.5:1 in participants in sinus rhythm (compared with approximately 5.5:1 in 
the youngest patients in both rhythm categories). In patients with the lowest eGFR values, the NT-
proBNP/BNP ratio was also approximately 10:1 for those in atrial fibrillation compared with 
around 7:1 in participants in sinus rhythm (compared to patients with the highest eGFR where the 
ratio was approximately 6.5:1 in patients in atrial fibrillation compared with around 5:1 in those not 
in atrial fibrillation).  
In contrast to the guidelines, most, but not all, trials have set different natriuretic peptide inclusion 
thresholds for patients with and without atrial fibrillation. However, the AF versus no AF 
multiplication factor for NT-pro BNP, versus BNP, varies two-fold from 1.5:1 to 3:0 in ongoing 
and recently completed trials; our data suggest that this factor is 1.4 (i.e. 8.03/5.75).  
In our study both levels of BNP and NT-proBNP decreased with increasing BMI. However, the 
decrease in NT-proBNP levels were more pronounced. Thus, BMI was associated with a negative  
NT-proBNP/BNP ratio which is in accordance with previous literature.
20
 It is unclear why levels of 
  
the natriuretic peptides is affected differently by BMI. As BNP, in contrast to NT-proBNP, is a 
substrate for neprilysin inhibition, a decrease in NT-proBNP/BNP ratio among patients treated with 
sacubitril/valsartan was expected.
21
 
Few other studies have examined the NT-proBNP/BNP ratio and most of these were small and 
involved patients without heart failure.
22-24
 The first large analysis of this type was carried out by 
the Valsartan Heart Failure Trial (Val-HeFT) investigators.
7
 In a subgroup of 3916 participants with 
chronic ambulatory HFrEF, the median concentrations of BNP and NT-proBNP were 99 pg/ml and 
895 pg/ml, respectively i.e. a ratio of 9.04:1. Presumably the difference in ratio reflects the older 
assays used in Val-HeFT. In a second and recent report from China, the ratio was more similar to 
what we found.
8
 The Chinese investigators studied 1464 hospitalized patients. Of these, 58% had 
HFrEF and the overall cohort was followed for a median period of 533 days. The median values of 
BNP and NT-proBNP were 375 pg/ml and 2029 pg/ml, respectively i.e. a ratio of 5.41:1.  
We found that BNP and NT-proBNP were predictive of the clinical outcomes investigated with 
hazard ratios per 1 standard deviation increase in peptide concentration of approximately 1.3-1.4 for 
all events other than pump failure death where the hazard ratio was 1.6-1.7. For each outcome of 
interest, except heart failure hospitalization, the hazard ratio was slightly larger for NT-proBNP 
than BNP but there was no significant difference for any outcome. Both peptides significantly 
improved the C-index when added to predictive models including other recognized prognostic 
variables. The two peptides increased the C-index similarly for each outcome examined. Although 
there are many comparisons of the diagnostic performance of BNP and NT-proBNP, few studies 
have compared the prognostic value of BNP and NT-proBNP in patients with HFrEF. The Val-
HeFT investigators found that NT-proBNP was a slightly but significantly better predictor of all-
cause mortality and, especially, heart failure hospitalization. However, in the recent study from 
China mentioned above, the investigators reported that BNP and NT-proBNP were similarly 
  
predictive for all-cause death or transplantation. Again, these differences may reflect the much older 
assays used in Val-HeFT. 
This study has several limitations. Most importantly, at enrollment, patients were required to have a 
plasma BNP ≥150 pg/ml (or NT-proBNP ≥600 pg/ml), or a BNP ≥100 pg/ml (or NT-proBNP ≥400 
pg/ml) if there had been a hospitalization for heart failure within the past 12 months. Consequently, 
we do not know about the relationship between BNP and NT-proBNP at lower plasma 
concentrations. Similarly, patients with an eGFR <30 ml/min/1.73m
2
 were excluded which is 
important, given the significant influence of renal function on natriuretic peptide levels. Because 
our patients were enrolled in a clinical trial, they were also, on average, younger than in the 
population at large and likely had less comorbidity. Lastly, we studied patients with HFrEF and the 
relationships described might be different in patients with heart failure and preserved ejection 
fraction and during acute decompensation as well as after acute myocardial infarction. Each of these 
factors limit the generalizability of our findings.  
In summary, when measured simultaneously in patients with HFrEF, the ratio of NT-proBNP to 
BNP is 6.25:1, substantially larger than the ratio currently recommended in guidelines or utilized in 
clinical trial inclusion criteria. Moreover, this ratio is quite different in patients with atrial 
fibrillation (8.03:1) compared to those without (5.75:1). At present, guidelines do not differentiate 
between atrial fibrillation and sinus rhythm and in the trials that do, the multiplication factor used is 
1.5-3.0, higher than the 1.4-fold higher rate found in the current analyses.  In both atrial fibrillation 
and sinus rhythm, age and renal function had a strong influence on the NT-proBNP to BNP ratio 
which increased to 10:1 in the oldest patients with atrial fibrillation and around 6.5:1 in those not in 
atrial fibrillation. Thus, there is no single, simple, conversion ratio for these two peptides. 
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Figure 1: NT-proBNP and BNP levels in all patients (A), in patients with (B) and without (C) 
atrial fibrillation: 
A: 
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C:
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: Ratio of NT-proBNP to BNP (NT-proBNP /BNP) according to decile of BNP: A) All 
patients. B) Patients with atrial fibrillation. C) Patients without atrial fibrillation. 
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Figure 3: NT-proBNP/BNP ratio in patients with and without atrial fibrillation, according to 
categories of: A) eGFR, B) age, C) BMI and D) LVEF 
A:  
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Supplementary figure 1: NT pro BNP/ BNP ratio according to treatment allocation 
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Table 1: Baseline characteristics according to median NT-proBNP/BNP ratio  
 
NT -proBNP/BNP ratio 
≤6.25 
NT-proBNP/BNP ratio  
>6.25 P-values 
Patients, n (%) 3219 (50) 3219 (50) 
 BNP, pg/mL 333 [213, 565.1] 307 [202, 554] 0.002 
NT-proBNP, pg/mL,  1406 [902, 2448] 2983 [1830, 5469] <0.0001 
Age, mean ± SD 61 ± 11 66 ± 11 <0.0001 
Female sex, n (%) 624 (19) 742 (23) 0.0003 
White, n (%) 1992 (62) 2220 (69) <0.0001 
Ischemic etiology, n (%) 2066 (64) 1837 (57) <0.0001 
HF duration, y, n (%)  
 
0.5598 
0-1 987 (31) 968 (30) 
 >1-5 1218 (38) 1260 (39) 
 >5 1014 (32) 991 (31) 
 NYHA class, n (%) 
  
0.0109 
I 8 (0.2) 19 (0.6) 
 II 2065 (64) 1966 (61) 
 III 1087 (34) 1181 (37) 
 IV 56 (2) 50 (2) 
 Body-mass index, m2/kg, median [Q1,Q3]   
 
<0.0001 
<18.5 42 (1) 96 (3) 
 18.5-24.9 898 (28) 1048(33) 
 25-29.9 1256 (39) 1170 (36) 
 30-34.9 674 (21) 604 (19) 
 ≥35 344 (11) 296(9.) 
 Ejection fraction (%) 29 ± 6 29 ± 6 0.5341 
Heart rate, beats/min 73 ± 13 75 ± 13 <0.0001 
Atrial fibrillation or flutter on ECG 490 (15) 1167 (36) <0.0001 
SBP, mmHg 128 ± 17 128 ± 17 0.905 
eGFR, mL/min per 1.73 m2 70 [58, 84] 62 [50, 74] <0.0001 
Creatinine; umol/L 91 [79, 107] 99 [84, 118] <0.0001 
eGFR, <60 mL/min per 1.73 m2, n (%) 876 (27) 1423 (44) <0.0001 
Jugular venous distension, n (%) 323 (10) 303 (9) 0.29 
Edema, n (%) 669 (21) 732 (23) 0.06 
Rales, n (%) 244 (8) 304 (9) 0.01 
Third heart sound, n(%) 325 (10) 303 (9) 0.36 
Medical history, n (%)  
  Myocardial infarction 1580 (49) 1239 (38) <0.0001 
Stroke 244 (8) 311 (10) 0.0029 
Atrial fibrillation 891 (28) 1562 (49) <0.0001 
Hypertension 2239 (70) 2326 (72) 0.017 
  
Diabetes 1127 (35) 1094 (34) 0.39 
Medication, n (%) 
   ACEI 2504(78) 2498 (78) 0.8574 
ARB 724 (22) 729 (23) 0.8815 
β-blockers 3006 (93) 2979 (93) 0.1883 
Diuretics 2538 (79) 2681 (83) <0.0001 
MRA 1847 (57) 1727 (54) 0.0026 
Digoxin 868 (27) 1084 (34) <0.0001 
Antiplatelets 1947(60) 1650 (51) <0.0001 
CRT P+D 211 (7) 236 (7) 0.2203 
ICD 495 (15) 459 (14) 0.2066 
 
 
 
 
 
 
 
  
  
Table 2: Predictors of NT-proBNP, BNP and the ratio of NT-proBNP to BNP (multivariable model) 
 NT-proBNP/BNP ratio Loge NT-proBNP LogeBNP 
 
β-Coef. (95% CI) P-value β-Coef. (95% CI) P-value β-Coef. (95% CI) P-value 
Age (+ 10 year) 0.45 (0.34-0.56) <0.001 0.03 (0.02-0.05) <0.001 -0.04 (-0.05--0.02) <0.001 
Sex (female) 1.33 (1.03-1.63) <0.001 0.14 (0.09-0.19) <0.001 -0.01 (-0.05-0.04) 0.78 
NYHA class 
  
    
I 0.27 (-1.46-2.00) 0.76 -0.08 (-0.37-0.21) 0.54 -0.14 (-0.40-0.12) 0.29 
II Ref. 
 
Ref.  Ref.  
III 0.06 (-0.18-0.30) 0.61 0.24 (0.20-0.29) <0.001 0.24 (0.20-0.27) <0.001 
IV -0.44 (-1.32-0.45) 0.33 0.43 (0.28-0.59) <0.001 0.51 (0.38-0.65) <0.001 
       
BMI (kg/m2) 
  
    
<18.5 1.90 (1.10-2.70) <0.001 0.41 (0.28-0.55) <0.001 0.20 (0.08-0.32) 0.001 
18.5-24.9 Ref. 
 
Ref.  Ref.  
25-29.9 -0.72 (-1.00--0.45) <0.001 -0.27 (-0.31--0.22) <0.001 -0.19 (-0.23--0.14) <0.001 
30-34.9 -1.08 (-1.41--0.74) <0.001 -0.43 (-0.49--0.38) <0.001 -0.32 (-0.37--0.27) <0.001 
>35 -0.99 (-1.43--0.56) <0.001 -0.53 (-0.61--0.46) <0.001 -0.42 (-0.49--0.36) <0.001 
       
Creatinine (+1 loge umol/L) 4.16 (3.66-4.66) <0.001 0.83 (0.74-0.91) <0.001 0.33 (0.25-0.40) <0.001 
Ejection fraction (+ 1 %) -0.01 (-0.03-0.01) 0.43 -0.02 (-0.02--0.02) <0.001 -0.02 (-0.02--0.01) <0.001 
Systolic blood pressure (+1 mmHg) -0.01 (-0.02-0.00) 0.02 0.00 (0.00-0.00) 0.14 0.00 (0.00-0.00) 0.66 
Myocardial infarction (Yes) -0.70 (-0.94-0.46) <0.001 -0.16 (-0.20--0.12) <0.001 -0.05 (-0.09--0.02) 0.004 
Atrial fibrillation* (Yes) 2.05 (1.78-2.32) <0.001 0.24 (0.19-0.29) <0.001 -0.03 (-0.08--0.02) 0.11 
Stroke (Yes) 0.43 (0.03-0.83) 0.04 0.04 (-0.03-0.11) 0.22 0.00 (-0.06-0.06) 0.97 
Diabetes (Yes) 0.01 (-0.22-0.26) 0.91 0.0 (-0.04-0.04) 0.92 0.00 (-0.04-0.03) 0.92 
Prior HF hosp. (Yes) -0.03 (-0.26-0.21) 0.84 -0.05 (-0.09--0.01) 0.01 -0.06 (-0.10--0.03) <0.001 
HF duration (Years) 
  
    
0-1 Ref. 
 
Ref.  Ref.  
  
>1-5 0.07 (-0.21-0.34) 0.63 0.05 (0.01-0.10) 0.03 0.07 (0.03-0.11) 0.001 
>5 -0.24 (-0.55-0.06) 0.11 -0.04 (-0.09-0.01) 0.15 0.02 (-0.03-0.06) 0.42 
Constant -14.55 (-17.10- -12.00) <0.001 4.41 (3.98-4.84) <0.001 5.26 (4.88-5.65 <0.001 
*Atrial fibrillation or flutter on ECG at screening 
BMI = body mass index 
β-Coef. = beta-coefficient 
HF = heart failure 
NYHA = New York Heart Association 
  
Table 3: Adjusted hazard ratios* for outcomes of interest according to 1 standard deviation increase 
of BNP or NT-proBNP. 
 
No. events HR (95% CI) P value 
CV death/HF hospitalization 1757   
BNP (Per 1 SD Increase)  1.37 (1.31-1.43) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.38 (1.32-1.45) <0.0001 
    
    
CV death 1089   
BNP (Per 1 SD Increase)  1.41 (1.33-1.49) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.45 (1.36-1.54) <0.0001 
    
    
HF hospitalization 1034   
BNP (Per 1 SD  Increase)  1.37 (1.29-1.46) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.36 (1.28-1.45) <0.0001 
    
    
All-cause mortality 1328   
BNP (Per 1 SD Increase)  1.38 (1.30-1.45) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.41 (1.33-1.49) <0.0001 
    
    
Sudden cardiac death 476   
BNP (Per 1 SD Increase)  1.32 (1.21-1.44) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.35 (1.23-1.49) <0.0001 
    
    
Pump failure death 292   
BNP (Per 1 SD  Increase)  1.60 (1.43-1.79) <0.0001 
    
NT-proBNP (Per 1 SD Increase)  1.66 (1.47-1.87) <0.0001 
 CV = cardiovascular, HF = heart failure, SD= standard deviation 
*All models were adjusted for age, sex, treatment effect, race, region, ejection fraction, NYHA 
class, body mass index, heart rate, systolic blood pressure, creatinine, prior heart failure 
hospitalizations, heart failure duration, atrial fibrillation, myocardial infarction, stroke and diabetes.
  
Table 4: C-index for predictive model without natriuretic peptides and for the addition of each of BNP and NT pro BNP, separately.  
 CV death or HF 
hospitalization 
CV death HF 
hospitalization 
All-cause 
mortality 
Sudden 
cardiac death 
Pump failure 
death 
 
 
C-index2 year 
(CI95%); P-value 
       
Baseline model
†
 0.63 
(0.61- 0.65) 
 
0.64 
(0.62-0.67) 
0.65 
(0.63-0.67) 
0.63 
(0.61-0.65) 
 
0.66 
(0.62-0.69) 
0.71 
(0.67-0.75) 
+ BNP 0.67 
(0.65-0.68) 
 
0.69 
(0.66-0.71) 
 
0.68 
(0.66-0.70) 
 
0.67 
(0.65-0.69) 
 
0.68 
(0.65-0.72) 
 
0.76 
(0.72-0.79) 
 
       
+ NT-pro BNP 0.66  
(0.65-0.68) 
P=0.33*  
0.68 
(0.66-0.70) 
P=0.31*  
0.68 
(0.65-0.70) 
P=0.26* 
0.66 
(0.64-0.68) 
P=0.20*  
0.68 
(0.65-0.71) 
P= 0.44*  
0.76 
(0.72-0.79) 
P= 0.83*  
       
†
Adjusted for age, sex, treatment effect, race, region, ejection fraction, NYHA class, body mass index, heart rate, systolic 
blood pressure, creatinine, prior heart failure hospitalizations, heart failure duration, atrial fibrillation, myocardial 
infarction, stroke and diabetes. Addition of each of BNP or NT-proBNP improved the C-index significantly for all 
outcomes: P<0.0001 for each peptide and for each event, except sudden death (BNP P=0.001; NT-proBNP P=0.009).  
*Compared with BNP 
 
 
 
 
 
